Pharsight

1. Adhansia Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722473	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Nov, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M (M)	Jun 28, 2024

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
35MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
45MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
55MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
70MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
85MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

ADHANSIA XR family patents

2. Adlarity patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835499	CORIUM	Systems and methods for long term transdermal administration	May, 2038 (14 years from now)
US10966936	CORIUM	Systems comprising a composite backing and methods for long term transdermal administration	Aug, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Mar 11, 2025

Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient

Market Authorisation Date: 11 March, 2022

Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type

Dosage: SYSTEM;TRANSDERMAL

Strength	Dosage	Availability
5MG/DAY	SYSTEM;TRANSDERMAL	Prescription
10MG/DAY	SYSTEM;TRANSDERMAL	Prescription

ADLARITY family patents

3. Airduo Digihaler patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17800844A	2020-06-03	Vectura Limited	Opposition rejected
EP17800844A	2020-02-14	CHIESI FARMACEUTICI S.p.A.	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11351317	TEVA PHARM	Drug delivery device with electronics	Feb, 2038 (14 years from now)
US11351317 (Pediatric)	TEVA PHARM	Drug delivery device with electronics	Aug, 2038 (14 years from now)
US11357935	TEVA PHARM	Drug delivery device with electronics	Sep, 2038 (14 years from now)
US11000653	TEVA PHARM	Inhaler	Dec, 2038 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M (M)	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

AIRDUO DIGIHALER family patents

4. Akeega patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11091459	JANSSEN BIOTECH	Niraparib compositions	Mar, 2038 (14 years from now)
US11673877	JANSSEN BIOTECH	Niraparib compositions	Mar, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
500MG;EQ 50MG BASE	TABLET;ORAL	Prescription
500MG;EQ 100MG BASE	TABLET;ORAL	Prescription

AKEEGA family patents

5. Altreno patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653656	DOW PHARM	Topical pharmaceutical compositions for treating skin conditions	Aug, 2038 (14 years from now)
US11324710	DOW PHARM	Topical pharmaceutical compositions for treating skin conditions	Aug, 2038 (14 years from now)

Drugs and Companies using TRETINOIN ingredient

Market Authorisation Date: 23 August, 2018

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION;TOPICAL

Strength	Dosage	Availability
0.05%	LOTION;TOPICAL	Prescription

ALTRENO family patents

6. Arazlo patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US11311482	June, 2023	Notice of Filing Date Accorded	Bausch Health Ireland Limited et al.	Padagis Israel Pharmaceuticals Ltd. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311482	BAUSCH	Topical compositions and methods for treating skin diseases	May, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Dec 18, 2022

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 18 December, 2019

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.00045	12 May, 2022	1		11 May, 2038

Strength	Dosage	Availability
0.045%	LOTION;TOPICAL	Prescription

ARAZLO family patents

7. Armonair Digihaler patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17800844A	2020-06-03	Vectura Limited	Opposition rejected
EP17800844A	2020-02-14	CHIESI FARMACEUTICI S.p.A.	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11351317	TEVA PHARM	Drug delivery device with electronics	Feb, 2038 (14 years from now)
US11351317 (Pediatric)	TEVA PHARM	Drug delivery device with electronics	Aug, 2038 (14 years from now)
US11357935	TEVA PHARM	Drug delivery device with electronics	Sep, 2038 (14 years from now)
US11000653	TEVA PHARM	Inhaler	Dec, 2038 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population (NPP)	Jul 9, 2024
New Strength (NS)	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.03MG/INH	POWDER;INHALATION	Discontinued
0.055MG/INH	POWDER;INHALATION	Discontinued
0.113MG/INH	POWDER;INHALATION	Discontinued
0.232MG/INH	POWDER;INHALATION	Discontinued

ARMONAIR DIGIHALER family patents

8. Aspruzyo Sprinkle patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10898444	SPIL	Extended release multiparticulates of ranolazine	Jan, 2038 (14 years from now)
US11510878	SPIL	NA	Jan, 2038 (14 years from now)

Drugs and Companies using RANOLAZINE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: NA

Dosage: GRANULES, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
1GM	GRANULES, EXTENDED RELEASE;ORAL	Prescription
500MG	GRANULES, EXTENDED RELEASE;ORAL	Prescription

ASPRUZYO SPRINKLE family patents

9. Austedo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11179386	TEVA BRANDED PHARM	Analogs of deutetrabenazine, their preparation and use	Mar, 2038 (14 years from now)
US11179386 (Pediatric)	TEVA BRANDED PHARM	Analogs of deutetrabenazine, their preparation and use	Sep, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 3, 2024
M (M)	Jun 24, 2024
Pediatric Exclusivity (PED)	Dec 24, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
6 mg, 9 mg and 12 mg	05 Apr, 2021	2		07 Mar, 2036

Strength	Dosage	Availability
6MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
12MG	TABLET;ORAL	Prescription

AUSTEDO family patents

10. Austedo Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11179386	TEVA	Analogs of deutetrabenazine, their preparation and use	Mar, 2038 (14 years from now)
US11179386 (Pediatric)	TEVA	Analogs of deutetrabenazine, their preparation and use	Sep, 2038 (14 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
6MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
12MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
24MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

AUSTEDO XR family patents

11. Balversa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077106	JANSSEN BIOTECH	Cancer treatment	Feb, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 2023-04-13

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 or fgfr2 genetic alterations, and progressed during or following prior platinum-containing chemother...

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
3 mg, 4 mg and 5 mg	12 Apr, 2023	1		02 Feb, 2038

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription

BALVERSA family patents

12. Baqsimi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10894133	ELI LILLY AND CO	Device for dispensing a fluid product	Jan, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Jul 24, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 24 July, 2019

Treatment: NA

Dosage: POWDER;NASAL

Strength	Dosage	Availability
3MG	POWDER;NASAL	Prescription

BAQSIMI family patents

13. Barhemsys patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357753	ACACIA	Rescue treatment of post operative nausea and vomiting	Feb, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: 2024-02-27

Market Authorisation Date: 26 February, 2020

Treatment: Treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
5MG/2ML (2.5MG/ML)	SOLUTION;INTRAVENOUS	Prescription
10MG/4ML (2.5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

BARHEMSYS family patents

14. Breztri Aerosphere patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11331442	ASTRAZENECA AB	Drug delivery systems and related methods	Oct, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination (NC)	Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

Strength	Dosage	Availability
0.16MG/INH;0.0048MG/INH;0.009MG/INH	AEROSOL, METERED;INHALATION	Prescription

BREZTRI AEROSPHERE family patents

15. Cerdelga patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888544	GENZYME CORP	Methods for treating Gaucher disease	Dec, 2038 (15 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with moderate to severe renal impairment; Long-term treatment of adults with gaucher disease type 1 who ...

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
84 mg	20 Aug, 2018	6	08 Sep, 2021	26 Jun, 2026	Deferred

Strength	Dosage	Availability
EQ 84MG BASE	CAPSULE;ORAL	Prescription

CERDELGA family patents

16. Consensi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350171	PURPLE BIOTECH	Celecoxib and amlodipine formulation and method of making the same	Jun, 2038 (14 years from now)
US10925835	PURPLE BIOTECH	Celecoxib and amlodipine formulation and method of making the same	Jun, 2038 (14 years from now)
US10945960	PURPLE BIOTECH	Celecoxib and amlodipine formulation and method of making the same	Jun, 2038 (14 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg/200 mg, 5 mg/200 mg, 10 mg/200 mg	29 Jun, 2020	1		14 Jun, 2038

CONSENSI family patents

17. Cotempla Xr-odt patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11166947	NEOS THERAPS INC	Effective dosing of a child for the treatment of ADHD with methylphenidate	Jan, 2038 (14 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

COTEMPLA XR-ODT family patents

18. Cysview Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11235168	PHOTOCURE ASA	Method of photodynamic therapy (PDT) for bladder cancer	Jan, 2038 (14 years from now)

Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2010

Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy

Dosage: FOR SOLUTION;INTRAVESICAL

CYSVIEW KIT family patents

19. Daptomycin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11759497	XELLIA PHARMS APS	Daptomycin formulations	Aug, 2038 (14 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 30 January, 2023

Treatment: NA

Dosage: POWDER;INTRAVENOUS

DAPTOMYCIN family patents

20. Dsuvia patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11672738	VERTICAL PHARMS	Apparatus and methods for dispensing oral transmucosal dosage forms	Feb, 2038 (14 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET;SUBLINGUAL

DSUVIA family patents

21. Dyanavel Xr 10 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590081	TRIS PHARMA INC	NA	Sep, 2038 (14 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 04 November, 2021

Treatment: Method of treating attention deficit hyperactivity disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

DYANAVEL XR 10 family patents

22. Empaveli patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040107	APELLIS PHARMS	Dosing regimens and related compositions and methods	Apr, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 14, 2026
Orphan Drug Exclusivity (ODE)	May 14, 2028
M (M)	Feb 8, 2026

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: 2025-05-14

Market Authorisation Date: 14 May, 2021

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by ...

Dosage: SOLUTION;SUBCUTANEOUS

EMPAVELI family patents

23. Erleada patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702508	JANSSEN BIOTECH	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer	Apr, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 2022-02-14

Market Authorisation Date: 14 February, 2018

Treatment: Treatment in combination with androgen deprivation therapy of non-metastatic, castration-resistant prostate cancer (nmcrpc) that improves metastasis free survival

Dosage: TABLET;ORAL

ERLEADA family patents

24. Evrysdi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11534444	GENENTECH INC	Treatment of SMA	Oct, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	May 27, 2029
New Chemical Entity Exclusivity (NCE)	Aug 7, 2025
New Patient Population (NPP)	May 27, 2025
M (M)	Oct 3, 2026

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 2024-08-07

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

EVRYSDI family patents

25. Ferriprox patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458103	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (14 years from now)
US10940116	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (14 years from now)
US10940115	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (14 years from now)
US11357731	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (14 years from now)
US10780055	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (14 years from now)
US11723874	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication (I)	Apr 30, 2024
Orphan Drug Exclusivity (ODE)	Apr 30, 2028

Drugs and Companies using DEFERIPRONE ingredient

Market Authorisation Date: 19 May, 2020

Treatment: Method of treating transfusional iron overload

Dosage: TABLET;ORAL

FERRIPROX family patents

26. Fintepla patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11406606 (Pediatric)	ZOGENIX INC	Formulation for inhibiting formation of 5-HT2B agonists and methods of using same	Feb, 2038 (14 years from now)
US11040018 (Pediatric)	ZOGENIX INC	Formulation for inhibiting formation of 5-HT2B agonists and methods of using same	Feb, 2038 (14 years from now)
US10603290 (Pediatric)	ZOGENIX INC	Formulation for inhibiting formation of 5-HT2B agonists and methods of using same	Feb, 2038 (14 years from now)
US10452815	ZOGENIX INC	Control system for control of distribution of medication	Jun, 2038 (14 years from now)
US10452815 (Pediatric)	ZOGENIX INC	Control system for control of distribution of medication	Dec, 2038 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 25, 2029
New Product (NP)	Jun 25, 2023
New Indication (I)	Mar 25, 2025
Pediatric Exclusivity (PED)	Sep 25, 2029

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome

Dosage: SOLUTION;ORAL

FINTEPLA family patents

27. Galafold patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11357765	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11633387	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11612594	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11786516	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11426396	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11612593	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11376244	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11357764	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11304940	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389436	AMICUS THERAP US	Methods of treating fabry patients having renal impairment	May, 2038 (14 years from now)
US11389437	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11357763	AMICUS THERAP US	Methods of treating fabry patients having renal impairment	May, 2038 (14 years from now)
US11357762	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11357761	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11666564	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10849889	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10849890	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10857141	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10471053	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10251873	AMICUS THERAP US	Methods of treating fabry patients having renal impairment	May, 2038 (14 years from now)
US10806727	AMICUS THERAP US	Methods of treating fabry patients having renal impairment	May, 2038 (14 years from now)
US10799491	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11458128	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10792279	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10792278	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10874656	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10874655	AMICUS THERAP US	Methods of treating fabry patients having renal impairment	May, 2038 (14 years from now)
US11278540	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10874657	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11278539	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11278536	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11278537	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US11278538	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)
US10857142	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	May, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 10, 2023
Orphan Drug Exclusivity (ODE)	Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 2022-08-10

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

GALAFOLD family patents

28. Gocovri patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077073	ADAMAS PHARMA	Methods of using amantadine compositions	Aug, 2038 (14 years from now)
US11065213	ADAMAS PHARMA	Amantadine compositions and preparations thereof	Aug, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 24, 2024

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time with...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

GOCOVRI family patents

29. Iheezo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792271	SINTETICA SA	Topical formulations of chloroprocaine and methods of using same	Sep, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Sep 27, 2025

Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 September, 2022

Treatment: Method of inducing ocular anesthesia

Dosage: GEL;OPHTHALMIC

IHEEZO family patents

30. Ingrezza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311532	NEUROCRINE	High dosage valbenazine formulation and compositions, methods, and kits related thereto	Sep, 2038 (14 years from now)
US11026939	NEUROCRINE	High dosage valbenazine formulation and compositions, methods, and kits related thereto	Sep, 2038 (14 years from now)
US11654142	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Nov, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 18, 2030

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: CAPSULE;ORAL

INGREZZA family patents

31. Jesduvroq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11117871	GLAXOSMITHKLINE	Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof	Mar, 2038 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11649217	GLAXOSMITHKLINE	Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof	Mar, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 1, 2028

Drugs and Companies using DAPRODUSTAT ingredient

NCE-1 date: 2027-02-01

Market Authorisation Date: 01 February, 2023

Treatment: A method of treating anemia

Dosage: TABLET;ORAL

JESDUVROQ family patents

32. Klisyri patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10669236	ALMIRALL	Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide	Sep, 2038 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617693	ALMIRALL	Methods of treating and/or preventing actinic keratosis	Mar, 2038 (14 years from now)
US11497750	ALMIRALL	Methods of treating and/or preventing actinic keratosis	Mar, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 14, 2025

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: 2024-12-14

Market Authorisation Date: 14 December, 2020

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT;TOPICAL

KLISYRI family patents

33. Korlym patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231983	CORCEPT THERAP	Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients	Aug, 2038 (14 years from now)
US10780097	CORCEPT THERAP	Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients	Aug, 2038 (14 years from now)
US10314850	CORCEPT THERAP	Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients	Aug, 2038 (14 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

KORLYM family patents

34. Levolet patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406108	GENUS LIFESCIENCES	Thyroid hormone oral dosage forms and methods of using the same	Mar, 2038 (14 years from now)
US10231931	GENUS LIFESCIENCES	Thyroid hormone oral dosage forms and methods of using the same	Mar, 2038 (14 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 06 June, 2003

Treatment: NA

Dosage: TABLET;ORAL

LEVOLET family patents

35. Levulan patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690914	DUSA	Methods for photodynamic therapy	Jan, 2038 (14 years from now)
US11077192	DUSA	Methods for photodynamic therapy	Jan, 2038 (14 years from now)
US11571478	DUSA	Methods for photodynamic therapy	Jan, 2038 (14 years from now)
US11135293	DUSA	Methods for photodynamic therapy	Jan, 2038 (14 years from now)
US10357567	DUSA	Methods for photodynamic therapy	Jan, 2038 (14 years from now)

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 03 December, 1999

Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy

Dosage: SOLUTION;TOPICAL

LEVULAN family patents

36. Liqrev patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11464778	CMP DEV LLC	Liquid oral formulations for sildenafil	Dec, 2038 (15 years from now)
US11337979	CMP DEV LLC	Liquid oral formulations for sildenafil	Dec, 2038 (15 years from now)
US11759468	CMP DEV LLC	Liquid oral formulations for sildenafil	Dec, 2038 (15 years from now)

Drugs and Companies using SILDENAFIL CITRATE ingredient

Market Authorisation Date: 28 April, 2023

Treatment: Liqrev is indicated for the treatment of pulmonary arterial hypertension (who group 1) in adults to improve exercise ability and delay clinical worsening

Dosage: SUSPENSION;ORAL

LIQREV family patents

37. Lorbrena patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11299500	PFIZER	Crystalline form of lorlatinib free base hydrate	Oct, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 2, 2023
Orphan Drug Exclusivity (ODE)	Mar 3, 2028
New Indication (I)	Mar 3, 2024

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: 2022-11-02

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

LORBRENA family patents

38. Lumakras patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10519146	AMGEN INC	KRAS G12C inhibitors and methods of using the same	May, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 28, 2026
Orphan Drug Exclusivity (ODE)	May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: 2025-05-28

Market Authorisation Date: 28 May, 2021

Treatment: NA

Dosage: TABLET;ORAL

LUMAKRAS family patents

39. Lumason patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335502	BRACCO	Freeze-dried formulation for gas-filled microvesicles	Jul, 2038 (14 years from now)
US10232061	BRACCO	Freeze-dried formulation for gas-filled microvesicles	Jul, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population (NPP)	Nov 13, 2022

Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient

Market Authorisation Date: 15 October, 2014

Treatment: NA

Dosage: FOR SUSPENSION;INTRAVENOUS

LUMASON family patents

40. Lutathera patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596276	AAA USA INC	Stable, concentrated radionuclide complex solutions	Jul, 2038 (14 years from now)
US10596278	AAA USA INC	Stable, concentrated radionuclide complex solutions	Jul, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 26, 2023
Orphan Drug Exclusivity (ODE)	Jan 26, 2025

Drugs and Companies using LUTETIUM DOTATATE LU-177 ingredient

NCE-1 date: 2022-01-26

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

LUTATHERA family patents

41. Mavenclad patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849919	EMD SERONO INC	Cladribine regimen for treating progressive forms of multiple sclerosis	Nov, 2038 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treating non-early spms by administering oral cladribine at a fixed dose per patient, per body weight and per treatment year, which fixed dose is 1.75 +/- 0.2 mg/kg, to be administered within months 1...

Dosage: TABLET;ORAL

MAVENCLAD family patents

42. Midazolam In 0.9% Sodium Chloride patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10966990	INFORLIFE	Midazolam in flexible bags	Jun, 2038 (14 years from now)

Drugs and Companies using MIDAZOLAM ingredient

Market Authorisation Date: 22 March, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE family patents

43. Myfembree patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11793812	MYOVANT SCIENCES	Methods of treating endometriosis	May, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 18, 2025
New Product (NP)	May 26, 2024
M (M)	Jan 27, 2026
New Indication (I)	Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 2024-12-18

Market Authorisation Date: 26 May, 2021

Treatment: Management of moderate to severe pain associated with endometriosis

Dosage: TABLET;ORAL

MYFEMBREE family patents

44. Norepinephrine Bitartrate In 0.9% Sodium Chloride patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11602508	NEVAKAR INJECTABLES	Norepinephrine compositions and methods therefor	Jan, 2038 (14 years from now)
US10568850	NEVAKAR INJECTABLES	Norepinephrine compositions and methods therefor	Jan, 2038 (14 years from now)
US10159657	NEVAKAR INJECTABLES	Norepinephrine compositions and methods therefor	Jan, 2038 (14 years from now)
US10420735	NEVAKAR INJECTABLES	Norepinephrine compositions and methods therefor	Jan, 2038 (14 years from now)
US10226436	NEVAKAR INJECTABLES	Norepinephrine compositions and methods therefor	Jan, 2038 (14 years from now)
US11413259	NEVAKAR INJECTABLES	Norepinephrine compositions and methods therefor	Jan, 2038 (14 years from now)

Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient

Market Authorisation Date: 06 October, 2022

Treatment: Indicated to raise blood pressure in adult patients with severe, acute hypotension

Dosage: SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents

45. Nubeqa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11168058	BAYER HEALTHCARE	Manufacture of a crystalline pharmaceutical product	Feb, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 30, 2024
New Indication (I)	Aug 5, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: 2023-07-31

Market Authorisation Date: 30 July, 2019

Treatment: NA

Dosage: TABLET;ORAL

NUBEQA family patents

46. Nuplazid patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10449185	ACADIA PHARMS INC	Formulations of pimavanserin	Aug, 2038 (14 years from now)
US10849891	ACADIA PHARMS INC	Formulations of pimavanserin	Aug, 2038 (14 years from now)
US10646480	ACADIA PHARMS INC	Formulations of pimavanserin	Aug, 2038 (14 years from now)
US11452721	ACADIA PHARMS INC	Formulations of pimavanserin	Aug, 2038 (14 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 28 June, 2018

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis

Dosage: CAPSULE;ORAL

NUPLAZID family patents

47. Nymalize patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11517563	AZURITY	NA	Apr, 2038 (14 years from now)
US10342787	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (14 years from now)
US10576070	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (14 years from now)
US11413277	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (14 years from now)
US11759457	AZURITY	Liquid nimodipine compositions	Apr, 2038 (14 years from now)
US11207306	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (14 years from now)

Drugs and Companies using NIMODIPINE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry a...

Dosage: SOLUTION;ORAL

NYMALIZE family patents

48. Opvee patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458091	INDIVIOR	Compositions and methods for the treatment of opioid overdose	Jul, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	May 22, 2026

Drugs and Companies using NALMEFENE HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2023

Treatment: Treating opioid overdose

Dosage: SPRAY;NASAL

OPVEE family patents

49. Orilissa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690854	ABBVIE	Methods of treating heavy menstrual bleeding	Apr, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis in a patient with moderate hepatic impairment

Dosage: TABLET;ORAL

ORILISSA family patents

50. Orserdu patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10385008	STEMLINE THERAP	Polymorphic forms of RAD1901-2HCL	Jan, 2038 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10745343	STEMLINE THERAP	Polymorphic forms of RAD1901-2HCl	Jan, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 27, 2028

Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-01-27

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of an er-positive breast cancer

Dosage: TABLET;ORAL

ORSERDU family patents

51. Osmolex Er patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213394	ADAMAS PHARMA	Composition and method for treating neurological disease	Feb, 2038 (14 years from now)
US10500171	ADAMAS PHARMA	Composition and method for treating neurological disease	Feb, 2038 (14 years from now)
US10500172	ADAMAS PHARMA	Composition and method for treating neurological disease	Feb, 2038 (14 years from now)
US10500170	ADAMAS PHARMA	Composition and method for treating neurological disease	Feb, 2038 (14 years from now)
US10512617	ADAMAS PHARMA	Composition and method for treating neurological disease	Feb, 2038 (14 years from now)
US10213393	ADAMAS PHARMA	Composition and method for treating neurological disease	Feb, 2038 (14 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 February, 2018

Treatment: Treatment of drug-induced extrapyramidal reaction in adult patients; A process for treating a patient suffering from parkinson's syndrome and in need of treatment

Dosage: TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER family patents

52. Otiprio patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11246863	ALK ABELLO	Ciprofloxacin otic composition and kits and method for using same	Nov, 2038 (15 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: NA

Dosage: INJECTABLE, SUSPENSION;OTIC

OTIPRIO family patents

53. Oxlumo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11261447	ALNYLAM PHARMS INC	Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression	Nov, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Oct 6, 2029
New Chemical Entity Exclusivity (NCE)	Nov 23, 2025
New Indication (I)	Oct 6, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: 2024-11-23

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

OXLUMO family patents

54. Pedmark patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596190	FENNEC PHARMS INC	Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy	Jan, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Sep 20, 2025
Orphan Drug Exclusivity (ODE)	Sep 20, 2029

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administrat...

Dosage: SOLUTION;INTRAVENOUS

PEDMARK family patents

55. Posluma patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11413360	BLUE EARTH	Dual mode radiotracer and—therapeutics	Nov, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 25, 2028

Drugs and Companies using FLOTUFOLASTAT F-18 GALLIUM ingredient

NCE-1 date: 2027-05-26

Market Authorisation Date: 25 May, 2023

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy...

Dosage: SOLUTION;INTRAVENOUS

POSLUMA family patents

56. Prevduo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456354	SLAYBACK PHARMA LLC	Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate	Oct, 2038 (14 years from now)
US11110054	SLAYBACK PHARMA LLC	Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate	Oct, 2038 (14 years from now)

Drugs and Companies using GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE ingredient

Market Authorisation Date: 23 February, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

PREVDUO family patents

57. Proair Digihaler patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11351317	TEVA BRANDED PHARM	Drug delivery device with electronics	Feb, 2038 (14 years from now)
US11357935	TEVA BRANDED PHARM	Drug delivery device with electronics	Sep, 2038 (14 years from now)
US11000653	TEVA BRANDED PHARM	Inhaler	Dec, 2038 (15 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

PROAIR DIGIHALER family patents

58. Pyrukynd patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11254652	AGIOS PHARMS INC	Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide	Nov, 2038 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234976	AGIOS PHARMS INC	Methods of using pyruvate kinase activators	Oct, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Feb 17, 2029
New Chemical Entity Exclusivity (NCE)	Feb 17, 2027

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: 2026-02-17

Market Authorisation Date: 17 February, 2022

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg

Dosage: TABLET;ORAL

PYRUKYND family patents

59. Qvar Redihaler patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11395888	NORTON WATERFORD	Inhalers and related methods	Jan, 2038 (14 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

QVAR REDIHALER family patents

60. Retevmo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10584124	LOXO ONCOLOGY INC	Crystalline forms	Oct, 2038 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786489	LOXO ONCOLOGY INC	Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile	Oct, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 8, 2025
Orphan Drug Exclusivity (ODE)	Sep 21, 2029

Drugs and Companies using SELPERCATINIB ingredient

NCE-1 date: 2024-05-08

Market Authorisation Date: 08 May, 2020

Treatment: Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, w...

Dosage: CAPSULE;ORAL

RETEVMO family patents

61. Rezzayo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11197909	CIDARA THERAPS	Compositions and methods for the treatment of fungal infections	Jul, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 22, 2030
New Chemical Entity Exclusivity (NCE)	Mar 22, 2028
Generating Antibiotic Incentives Now (GAIN)	Mar 22, 2033

Drugs and Companies using REZAFUNGIN ACETATE ingredient

NCE-1 date: 2032-03-22

Market Authorisation Date: 22 March, 2023

Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration

Dosage: POWDER;INTRAVENOUS

REZZAYO family patents

62. Rinvoq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564922	ABBVIE	Methods of treating crohn's disease and ulcerative colitis	Mar, 2038 (14 years from now)
US11607411	ABBVIE	Methods of treating Crohn's disease and ulcerative colitis	Mar, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 16, 2024
New Indication (I)	Jan 14, 2025

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults with moderately to severely active crohn's disease who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with moderately to severely a...

Dosage: TABLET, EXTENDED RELEASE;ORAL

RINVOQ family patents

63. Rivfloza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11286488	NOVO	Methods and compositions for inhibiting expression of LDHA	Oct, 2038 (14 years from now)
US11661604	NOVO	Methods and compositions for inhibiting expression of LDHA	Oct, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 29, 2030
New Chemical Entity Exclusivity (NCE)	Sep 29, 2028

Drugs and Companies using NEDOSIRAN SODIUM ingredient

NCE-1 date: 2027-09-30

Market Authorisation Date: 29 September, 2023

Treatment: Method of treating primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;INJECTION

RIVFLOZA family patents

64. Rozlytrek patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398693	GENENTECH INC	Pharmaceutical compositions and dosage forms	Jul, 2038 (14 years from now)
US11253515	GENENTECH INC	Pharmaceutical compositions and dosage forms	Jul, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 15, 2026
New Chemical Entity Exclusivity (NCE)	Aug 15, 2024

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: 2023-08-16

Market Authorisation Date: 15 August, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

ROZLYTREK family patents

65. Ryaltris patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11679210	GLENMARK SPECIALTY	Dispensing device and pharmaceutical composition for the treatment of rhinitis	Sep, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Jan 13, 2025

Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 January, 2022

Treatment: NA

Dosage: SPRAY, METERED;NASAL

RYALTRIS family patents

66. Sincalide patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11110063	MAIA PHARMS INC	Storage stable sincalide formulations	Apr, 2038 (14 years from now)
US11737983	MAIA PHARMS INC	Storage stable sincalide formulations	Apr, 2038 (14 years from now)
US11318100	MAIA PHARMS INC	Storage stable sincalide formulations	Apr, 2038 (14 years from now)

Drugs and Companies using SINCALIDE ingredient

Market Authorisation Date: 22 November, 2022

Treatment: Diagnosis of gall bladder disorders or other diagnostic imaging by stimulating gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration...

Dosage: POWDER;INTRAVENOUS

SINCALIDE family patents

67. Sotalol Hydrochloride patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512620	ALTATHERA PHARMS LLC	Method of initiating and escalating sotalol hydrochloride dosing	Aug, 2038 (14 years from now)
US11696902	ALTATHERA PHARMS LLC	Method of initiating and escalating sotalol hydrochloride dosing	Aug, 2038 (14 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 02 July, 2009

Treatment: Dosing regimen for intravenous sotalol for administration in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation.

Dosage: SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE family patents

68. Sublocade patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646484	INDIVIOR INC	Methods to treat opioid use disorder	Jun, 2038 (14 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 30 November, 2017

Treatment: Treatment of moderate to severe opioid use disorder

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

SUBLOCADE family patents

69. Sunlenca patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11267799	GILEAD SCIENCES INC	Solid forms of an HIV capsid inhibitor	Aug, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 22, 2027

Drugs and Companies using LENACAPAVIR SODIUM ingredient

NCE-1 date: 2026-12-22

Market Authorisation Date: 22 December, 2022

Treatment: NA

Dosage: TABLET;ORAL

SUNLENCA family patents

70. Sunosi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11648232	AXSOME MALTA	Methods and compositions for treating excessive sleepiness	Jun, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 17, 2024
Orphan Drug Exclusivity (ODE)	Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness with a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily

Dosage: TABLET;ORAL

SUNOSI family patents

71. Sunosi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912754	JAZZ	Methods and compositions for treating excessive sleepiness	Jun, 2038 (14 years from now)
US10959976	JAZZ	Methods and compositions for treating excessive sleepiness	Jun, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 17, 2024
Orphan Drug Exclusivity (ODE)	Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days f...

Dosage: TABLET;ORAL

SUNOSI family patents

72. Symtuza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786518	JANSSEN PRODS	Compositions and methods of treating HIV	Jul, 2038 (14 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 17 July, 2018

Treatment: Treatment of hiv-1 infection in adult or pediatric patients (>=40 kg) with <50 copies/ml hiv-1 rna after >= 6 months on prior antiretroviral regimen and no known darunavir or tenofovir resistance-asso...

Dosage: TABLET;ORAL

SYMTUZA family patents

73. Tadliq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11382917	CMP DEV LLC	Liquid oral formulations for tadalafil	Dec, 2038 (15 years from now)
US11666576	CMP DEV LLC	Liquid oral formulations for tadalafil	Dec, 2038 (15 years from now)

Drugs and Companies using TADALAFIL ingredient

Market Authorisation Date: 17 June, 2022

Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability

Dosage: SUSPENSION;ORAL

TADLIQ family patents

74. Tafinlar patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504333	NOVARTIS	Pharmaceutical composition	Jun, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 16, 2030
New Product (NP)	Mar 16, 2026

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Market Authorisation Date: 16 March, 2023

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

TAFINLAR family patents

75. Thiola Ec patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458104	MISSION PHARMACAL CO	NA	Nov, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
ODE* (ODE*)	Jun 28, 2026

Drugs and Companies using TIOPRONIN ingredient

Market Authorisation Date: 28 June, 2019

Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria

Dosage: TABLET, DELAYED RELEASE;ORAL

THIOLA EC family patents

76. Tukysa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11207324	SEAGEN	Treatment of HER2 positive cancers	Apr, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jan 19, 2030
New Chemical Entity Exclusivity (NCE)	Apr 17, 2025
New Indication (I)	Jan 19, 2026

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: Combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing unresectable or metastatic colorectal cancer

Dosage: TABLET;ORAL

TUKYSA family patents

77. Turalio patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435404	DAIICHI SANKYO INC	Formulations of a compound modulating kinases	Jul, 2038 (14 years from now)
US10961240	DAIICHI SANKYO INC	Formulations of a compound modulating kinases	Jul, 2038 (14 years from now)
US10941142	DAIICHI SANKYO INC	Formulations of a compound modulating kinases	Jul, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 2, 2026
New Chemical Entity Exclusivity (NCE)	Aug 2, 2024
ODE* (ODE*)	Aug 2, 2026

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

NCE-1 date: 2023-08-03

Market Authorisation Date: 02 August, 2019

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

TURALIO family patents

78. Twyneo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10420743	GALDERMA LABS LP	Methods and compositions for the treatment of acne	Jul, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination (NC)	Jul 26, 2024

Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient

Market Authorisation Date: 26 July, 2021

Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older

Dosage: CREAM;TOPICAL

TWYNEO family patents

79. Tymlos patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11782041	RADIUS	Abaloparatide formulations and methods of testing, storing, modifying, and using same	Apr, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M (M)	Sep 20, 2024
New Indication (I)	Dec 19, 2025

Drugs and Companies using ABALOPARATIDE ingredient

Market Authorisation Date: 28 April, 2017

Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Treatment to increase bone density in men with osteoporosis at high risk for fracture

Dosage: SOLUTION;SUBCUTANEOUS

TYMLOS family patents

80. Tymlos patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10996208	RADIUS HEALTH INC	Abaloparatide formulations and methods of testing, storing, modifying, and using same	Apr, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M (M)	Sep 20, 2024
New Indication (I)	Dec 19, 2025

Drugs and Companies using ABALOPARATIDE ingredient

Market Authorisation Date: 28 April, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

TYMLOS family patents

81. Veklury patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10675296	GILEAD SCIENCES INC	Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections	Jul, 2038 (14 years from now)
US11266681	GILEAD SCIENCES INC	Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections	Jul, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 22, 2025
New Patient Population (NPP)	Apr 25, 2025
New Dosing Schedule (D)	Jan 21, 2025
M (M)	Jul 13, 2026

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 2024-10-22

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in no...

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

VEKLURY family patents

82. Vevye patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154513	NOVALIQ GMBH	Semifluorinated compounds	Nov, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	May 30, 2026

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 30 May, 2023

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION;OPHTHALMIC

VEVYE family patents

83. Vtama patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10647649	DERMAVANT SCI	Process for preparing tapinarof	Nov, 2038 (14 years from now)
US11597692	DERMAVANT SCI	Process for preparing tapinarof	Nov, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: 2026-05-23

Market Authorisation Date: 23 May, 2022

Treatment: NA

Dosage: CREAM;TOPICAL

VTAMA family patents

84. Wegovy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11752198	NOVO	GLP-1 compositions and uses thereof	Aug, 2038 (14 years from now)
US10888605	NOVO	GLP-1 compositions and uses thereof	Aug, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Jun 4, 2024
New Dosing Schedule (D)	Jul 21, 2026
New Patient Population (NPP)	Dec 23, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

WEGOVY family patents

85. Xdemvy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835517	TARSUS	Methods for treating ocular demodex using isoxazoline parasiticide formulations	Dec, 2038 (15 years from now)
US11197847	TARSUS	Isoxazoline parasiticide formulations and methods for treating blepharitis	Dec, 2038 (15 years from now)
US11752137	TARSUS	Ophthalmic compositions for treating ocular Demodex using lotilaner formulations	Dec, 2038 (15 years from now)
US11690827	TARSUS	Methods for treating ocular Demodex using lotilaner formulations	Dec, 2038 (15 years from now)
US11690826	TARSUS	Methods for treating demodex blepharitis using lotilaner formulations	Dec, 2038 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 24, 2028

Drugs and Companies using LOTILANER ingredient

NCE-1 date: 2027-07-25

Market Authorisation Date: 24 July, 2023

Treatment: Treatment of demodex blepharitis via topical administration to an ocular surface

Dosage: SOLUTION/DROPS;OPHTHALMIC

XDEMVY family patents

86. Xofluza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11261198	GENENTECH INC	Process for preparing substituted polycyclic pyridone derivative and crystal thereof	Sep, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 24, 2023

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: 2022-10-24

Market Authorisation Date: 24 October, 2018

Treatment: NA

Dosage: TABLET;ORAL

XOFLUZA family patents

87. Xyosted (autoinjector) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646495	ANTARES PHARMA INC	Testosterone ester triglyceride formulations	Aug, 2038 (14 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

XYOSTED (AUTOINJECTOR) family patents

88. Ycanth patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11147790	VERRICA PHARMS	Treatment of cutaneous disorders	Aug, 2038 (14 years from now)

Drugs and Companies using CANTHARIDIN ingredient

Market Authorisation Date: 21 July, 2023

Treatment: Topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older; Topical treatment of skin lesions caused by an infection with molluscum contagiosum in adult and pe...

Dosage: SOLUTION;TOPICAL

YCANTH family patents

89. Zejula patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091459	GLAXOSMITHKLINE	Niraparib compositions	Mar, 2038 (14 years from now)
US11673877	GLAXOSMITHKLINE	Niraparib compositions	Mar, 2038 (14 years from now)

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 26 April, 2023

Treatment: A method of treatment of recurrent ovarian cancer or fallopian tube cancer associated with deleterious or suspected deleterious germline brca-mutation; A method of treatment of ovarian cancer or fallo...

Dosage: TABLET;ORAL

ZEJULA family patents

90. Zonisade patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478456	AZURITY	NA	Aug, 2038 (14 years from now)
US11529333	AZURITY	Oral pharmaceutical composition comprising zonisamide and process of preparation thereof	Aug, 2038 (14 years from now)

Drugs and Companies using ZONISAMIDE ingredient

Market Authorisation Date: 15 July, 2022

Treatment: A method of treating seizures

Dosage: SUSPENSION;ORAL

ZONISADE family patents

List of large molecules

1. List of Eylea large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US10918754	REGENERON PHARMACEUTICALS, INC.	Sterilisation method	Mar, 2038 (14 years from now)
US10905786	REGENERON PHARMACEUTICALS, INC.	Sterilisation method	Mar, 2038 (14 years from now)

Ingredients: AFLIBERCEPT

Strength	Dosage	Availability
EQ 2.5MG BASE;200MG	TABLET;ORAL	Discontinued
EQ 5MG BASE;200MG	TABLET;ORAL	Discontinued
EQ 10MG BASE;200MG	TABLET;ORAL	Discontinued

Strength	Dosage	Availability
8.6MG	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
17.3MG	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
25.9MG	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
350MG/VIAL	POWDER;INTRAVENOUS	Prescription
500MG/VIAL	POWDER;INTRAVENOUS	Prescription

Strength	Dosage	Availability
8MG;EQ 2MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
12MG;EQ 3MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
16MG;EQ 4MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
4MG;EQ 1MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP15813093A	2022-07-13	Elkington and Fife LLP	Granted and Under Opposition

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
137 mg	16 Jan, 2018	1		02 Dec, 2030
68.5 mg	30 Apr, 2020	1		04 Dec, 2034

Strength	Dosage	Availability
EQ 68.5MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 137MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mg and 80 mg	12 Apr, 2021	4		10 Aug, 2040
60 mg	14 Feb, 2022	1		10 Aug, 2040

Strength	Dosage	Availability
EQ 40MG BASE	CAPSULE;ORAL	Prescription
EQ 60MG BASE	CAPSULE;ORAL	Prescription
EQ 80MG BASE	CAPSULE;ORAL	Prescription

Strength	Dosage	Availability
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10357567	October, 2021	Terminated-Dismissed	DUSA Pharmaceuticals, Inc. et al.	Biofrontera Inc. et al.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10596276	October, 2020	Institution Denied	Advanced Accelerator Applications SA	Evergreen Theragnostics, Inc.
US10596278	October, 2020	Terminated-Denied	Advanced Accelerator Applications SA	Evergreen Theragnostics, Inc.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10849919	February, 2023	Terminated-Settled	Ares Trading SA	Hopewell Pharma Ventures, Inc. et al.

Strength	Dosage	Availability
50MG/50ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription
100MG/100ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Dosage	Availability
EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
34 mg	29 Apr, 2020	5		27 Aug, 2038
10 mg	29 Apr, 2020	1		03 Jun, 2028

Strength	Dosage	Availability
3MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION;ORAL	Discontinued
6MG/ML	SOLUTION;ORAL	Prescription

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription
EQ 200MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
EQ 86MG BASE	TABLET;ORAL	Prescription
EQ 345MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
EQ 129MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 161MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 193MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 258MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued

Pharsight

Drug Patents Expiring in 2038

1. Adhansia Xr patents expiration Share with your colleague

ADHANSIA XR family patents

2. Adlarity patents expiration Share with your colleague

ADLARITY family patents

3. Airduo Digihaler patents expiration Share with your colleague

AIRDUO DIGIHALER family patents

4. Akeega patents expiration Share with your colleague

AKEEGA family patents

5. Altreno patents expiration Share with your colleague

ALTRENO family patents

6. Arazlo patents expiration Share with your colleague

ARAZLO family patents

7. Armonair Digihaler patents expiration Share with your colleague

ARMONAIR DIGIHALER family patents

8. Aspruzyo Sprinkle patents expiration Share with your colleague

ASPRUZYO SPRINKLE family patents

9. Austedo patents expiration Share with your colleague

AUSTEDO family patents

10. Austedo Xr patents expiration Share with your colleague

AUSTEDO XR family patents

11. Balversa patents expiration Share with your colleague

BALVERSA family patents

12. Baqsimi patents expiration Share with your colleague

BAQSIMI family patents

13. Barhemsys patents expiration Share with your colleague

BARHEMSYS family patents

14. Breztri Aerosphere patents expiration Share with your colleague

BREZTRI AEROSPHERE family patents

15. Cerdelga patents expiration Share with your colleague

CERDELGA family patents

16. Consensi patents expiration Share with your colleague

CONSENSI family patents

17. Cotempla Xr-odt patents expiration Share with your colleague

COTEMPLA XR-ODT family patents

18. Cysview Kit patents expiration Share with your colleague

CYSVIEW KIT family patents

19. Daptomycin patents expiration Share with your colleague

DAPTOMYCIN family patents

20. Dsuvia patents expiration Share with your colleague

DSUVIA family patents

21. Dyanavel Xr 10 patents expiration Share with your colleague

DYANAVEL XR 10 family patents

22. Empaveli patents expiration Share with your colleague

EMPAVELI family patents

23. Erleada patents expiration Share with your colleague

ERLEADA family patents

24. Evrysdi patents expiration Share with your colleague

EVRYSDI family patents

25. Ferriprox patents expiration Share with your colleague

FERRIPROX family patents

26. Fintepla patents expiration Share with your colleague

FINTEPLA family patents

27. Galafold patents expiration Share with your colleague

GALAFOLD family patents

28. Gocovri patents expiration Share with your colleague

GOCOVRI family patents

29. Iheezo patents expiration Share with your colleague

IHEEZO family patents

30. Ingrezza patents expiration Share with your colleague

INGREZZA family patents

31. Jesduvroq patents expiration Share with your colleague

JESDUVROQ family patents

32. Klisyri patents expiration Share with your colleague

KLISYRI family patents

33. Korlym patents expiration Share with your colleague

KORLYM family patents

34. Levolet patents expiration Share with your colleague

LEVOLET family patents

35. Levulan patents expiration Share with your colleague

LEVULAN family patents

36. Liqrev patents expiration Share with your colleague

LIQREV family patents

37. Lorbrena patents expiration Share with your colleague

LORBRENA family patents

38. Lumakras patents expiration Share with your colleague

LUMAKRAS family patents

39. Lumason patents expiration Share with your colleague

LUMASON family patents

1. Adhansia Xr patents expiration

2. Adlarity patents expiration

3. Airduo Digihaler patents expiration

4. Akeega patents expiration

5. Altreno patents expiration

6. Arazlo patents expiration

7. Armonair Digihaler patents expiration

8. Aspruzyo Sprinkle patents expiration

9. Austedo patents expiration

10. Austedo Xr patents expiration

11. Balversa patents expiration

12. Baqsimi patents expiration

13. Barhemsys patents expiration

14. Breztri Aerosphere patents expiration

15. Cerdelga patents expiration

16. Consensi patents expiration

17. Cotempla Xr-odt patents expiration

18. Cysview Kit patents expiration

19. Daptomycin patents expiration

20. Dsuvia patents expiration

21. Dyanavel Xr 10 patents expiration

22. Empaveli patents expiration

23. Erleada patents expiration

24. Evrysdi patents expiration

25. Ferriprox patents expiration

26. Fintepla patents expiration

27. Galafold patents expiration

28. Gocovri patents expiration

29. Iheezo patents expiration

30. Ingrezza patents expiration

31. Jesduvroq patents expiration

32. Klisyri patents expiration

33. Korlym patents expiration

34. Levolet patents expiration

35. Levulan patents expiration

36. Liqrev patents expiration

37. Lorbrena patents expiration

38. Lumakras patents expiration

39. Lumason patents expiration

40. Lutathera patents expiration

41. Mavenclad patents expiration

42. Midazolam In 0.9% Sodium Chloride patents expiration

43. Myfembree patents expiration

44. Norepinephrine Bitartrate In 0.9% Sodium Chloride patents expiration

45. Nubeqa patents expiration

46. Nuplazid patents expiration

47. Nymalize patents expiration

48. Opvee patents expiration

49. Orilissa patents expiration

50. Orserdu patents expiration

51. Osmolex Er patents expiration

52. Otiprio patents expiration

53. Oxlumo patents expiration

54. Pedmark patents expiration

55. Posluma patents expiration

56. Prevduo patents expiration

57. Proair Digihaler patents expiration

58. Pyrukynd patents expiration

59. Qvar Redihaler patents expiration

60. Retevmo patents expiration

61. Rezzayo patents expiration

62. Rinvoq patents expiration

63. Rivfloza patents expiration

64. Rozlytrek patents expiration

65. Ryaltris patents expiration

66. Sincalide patents expiration

67. Sotalol Hydrochloride patents expiration

68. Sublocade patents expiration

69. Sunlenca patents expiration

70. Sunosi patents expiration

71. Sunosi patents expiration

72. Symtuza patents expiration

73. Tadliq patents expiration

74. Tafinlar patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10596190	October, 2021	Final Written Decision	Oregon Health & Science University et al.	Hope Medical Enterprises, Inc.

Strength	Dosage	Availability
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
0.04MG/INH	AEROSOL, METERED;INHALATION	Prescription
0.08MG/INH	AEROSOL, METERED;INHALATION	Prescription

Strength	Dosage	Availability
15MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
45MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML)	SOLUTION;INJECTION	Prescription
EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML)	SOLUTION;INJECTION	Prescription
EQ 160MG BASE/ML (EQ 160MG BASE/ML)	SOLUTION;INJECTION	Prescription

Strength	Dosage	Availability
100MG/0.5ML (100MG/0.5ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription
300MG/1.5ML (200MG/ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription

Strength	Dosage	Availability
EQ 75MG BASE	TABLET;ORAL	Prescription
EQ 150MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
100MG	TABLET, DELAYED RELEASE;ORAL	Prescription
300MG	TABLET, DELAYED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription
100MG/20ML (5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Dosage	Availability
0.25MG/0.5ML (0.25MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
0.5MG/0.5ML (0.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
1MG/0.5ML (1MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
1.7MG/0.75ML (1.7MG/0.75ML)	SOLUTION;SUBCUTANEOUS	Prescription
2.4MG/0.75ML (2.4MG/0.75ML)	SOLUTION;SUBCUTANEOUS	Prescription